These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37440017)

  • 21. Improving retinal mitochondrial function as a treatment for age-related macular degeneration.
    Ebeling MC; Polanco JR; Qu J; Tu C; Montezuma SR; Ferrington DA
    Redox Biol; 2020 Jul; 34():101552. PubMed ID: 32446621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead.
    Shah RR; Stonier PD
    J Clin Pharm Ther; 2019 Feb; 44(1):6-22. PubMed ID: 30218625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
    Tolentino MJ; Dennrick A; John E; Tolentino MS
    Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage.
    Nashine S; Cohen P; Chwa M; Lu S; Nesburn AB; Kuppermann BD; Kenney MC
    Cell Death Dis; 2017 Jul; 8(7):e2951. PubMed ID: 28726777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lacoste AMB; Visanji NP; Lang AE; Fox SH; Brotchie JM
    Neuropharmacology; 2019 Mar; 147():11-27. PubMed ID: 29907424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X; Sun X
    Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.
    Strecker K; Adamaszek M; Ohm S; Wegner F; Beck J; Schwarz J
    J Neural Transm (Vienna); 2012 Nov; 119(11):1351-9. PubMed ID: 22569849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Summarize drug dosage forms in treatment of age-related macular degeneration disease].
    Du MB; Liu SZ; Xu K; Liang LN; He AP; Yao Y; Liu YM
    Zhongguo Zhong Yao Za Zhi; 2017 Feb; 42(4):628-633. PubMed ID: 28959828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of metformin and development of dry age-related macular degeneration in a U.S. insurance claims database.
    Eton EA; Wubben TJ; Besirli CG; Hua P; McGeehan B; VanderBeek BL
    Eur J Ophthalmol; 2022 Jan; 32(1):417-423. PubMed ID: 33607930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of circular RNA-mediated regulation of L-DOPA to improve wet age-related macular degeneration.
    Jia X; Sun Y; Wang T; Zhong L; Deng J; Zhu X
    Gene; 2023 Apr; 861():147247. PubMed ID: 36736867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Gerlach M; Beck J; Riederer P; van den Buuse M
    J Neural Transm (Vienna); 2011 Dec; 118(12):1727-32. PubMed ID: 21274579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory aspects of drug approval for macular degeneration.
    Gryziewicz L
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2092-8. PubMed ID: 16316706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.
    Fong AH; Lai TY
    Clin Interv Aging; 2013; 8():467-83. PubMed ID: 23766636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatments targeting autophagy ameliorate the age-related macular degeneration phenotype in mice lacking APOE (apolipoprotein E).
    Vessey KA; Jobling AI; Tran MX; Wang AY; Greferath U; Fletcher EL
    Autophagy; 2022 Oct; 18(10):2368-2384. PubMed ID: 35196199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Status of therapies in development for the treatment of age-related macular degeneration.
    Hunt DW; Margaron P
    IDrugs; 2003 May; 6(5):464-9. PubMed ID: 12789601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigational drugs in clinical trials for macular degeneration.
    Tolentino MJ; Tolentino AJ
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1067-1085. PubMed ID: 35962560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Results of the use of antioxidant and angioprotective agents in type 2 diabetes patients with diabetic retinopathy and age-related macular degeneration].
    Moshetova LK; Vorob'eva IV; Alekseev IB; Mikhaleva LG
    Vestn Oftalmol; 2015; 131(3):34-44. PubMed ID: 26310005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New approaches and potential treatments for dry age-related macular degeneration.
    Damico FM; Gasparin F; Scolari MR; Pedral LS; Takahashi BS
    Arq Bras Oftalmol; 2012; 75(1):71-6. PubMed ID: 22552424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke.
    Sharma S; Nozohouri S; Vaidya B; Abbruscato T
    Life Sci; 2021 Jun; 274():119343. PubMed ID: 33716063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review.
    Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):761-767. PubMed ID: 31540558
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.